Skip to main content
. 2020 Oct 6;22:791–802. doi: 10.1016/j.omtn.2020.10.001

Figure 1.

Figure 1

Clinical Relevance of SYT13 Expression and Design of AmNA-Modified Anti-SYT13 ASOs

(A) Immunohistochemical analysis of a pathological T4a tumor. SYT13 expression at the primary cancer component was associated with peritoneal metastasis. (B) Prognosis and SYT13 expression in TCGA and Kaplan-Meier-plotter cohorts. (C) The predicted loop structure of SYT13 mRNA. (D) Structures of AmNA-modified anti-SYT13 ASOs. (E) Initial screening of ASOs according to knockdown efficacy of SYT13 expression. (F) Second screening of ASOs according to concentration-dependent knockdown efficacy of SYT13 expression. Error bars indicate the standard deviation.